Fractyl Health announced the appointment of Adrian Kimber as Chief Commercial Officer. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Kimber most recently served as Global VP & Commercial Head at Biotronik Neuro, where he spearheaded the introduction of daily remote monitoring and Proactive Care for patients with spinal cord stimulation devices.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
- Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year
- Fractyl Health Gains FDA Nod to Investigate Revita Device
- Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs